Literature DB >> 12016263

Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.

Giulia Chiesa1, Elena Monteggia, Marta Marchesi, Paolo Lorenzon, Massimo Laucello, Vito Lorusso, Carlo Di Mario, Evangelia Karvouni, Roger S Newton, Charles L Bisgaier, Guido Franceschini, Cesare R Sirtori.   

Abstract

Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. In previous studies, administration of recombinant AIM-phospholipid (AIM-PL) complexes to hypercholesterolemic rabbits markedly inhibited neointimal formation after arterial injury; moreover, repeated injections of AIM-PL in apoE-deficient mice significantly reduced atherosclerosis progression. The objective of the present study was to determine if a single localized infusion of AIM-PL complexes administered directly to atheromatous lesions could promote plaque regression. Lipid-rich, atheromatous plaques were generated at both common carotid arteries of 25 rabbits by applying a perivascular electric injury, followed by 1.5% cholesterol diet for 90 days. Rabbits were infused with either saline, phospholipid vesicles, or 3 different AIM-PL doses (250, 500, or 1000 mg of protein) delivered through an intravascular ultrasound (IVUS) catheter positioned at the origin of the right carotid. The lesions at the left carotid artery were therefore exposed to the agents systemically. Infusion of AIM-PL at the 2 highest doses caused reduction of right carotid artery plaque area by the end a 90-minute infusion as assessed by IVUS analysis. Plaque area regression was confirmed by histology in carotid arteries receiving direct (500 and 1000 mg doses) and systemic (500 mg dose) delivery, 72 hours after the start of the treatment. Plaque lipid content was associated with significant and similar decreases in Oil Red O staining in both arteries. These results suggest AIM-PL complexes enhanced lipid removal from arteries is the mechanism responsible for the observed plaque changes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12016263     DOI: 10.1161/01.res.0000018422.31717.ee

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Can we stabilize unstable plaque?

Authors:  Rodolfo Paoletti; Andrea Cignarella
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

2.  Therapeutic reduction of coronary atheromatous plaque burden using bioengineered apoA-I Milano.

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

Review 3.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids.

Authors:  Guo-Jun Zhao; Kai Yin; Yu-Chang Fu; Chao-Ke Tang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 5.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 6.  New imaging techniques for diagnosing coronary artery disease.

Authors:  Esteban Escolar; Guy Weigold; Anthon Fuisz; Neil J Weissman
Journal:  CMAJ       Date:  2006-02-14       Impact factor: 8.262

Review 7.  The paraoxonase gene family and atherosclerosis.

Authors:  David Seo; Pascal Goldschmidt-Clermont
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

Review 8.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

9.  Regulation of expression of apolipoprotein A-I by selenium status in human liver hepatoblastoma cells.

Authors:  Jessica A Stahle; Hema Vunta; C Channa Reddy; K Sandeep Prabhu
Journal:  Eur J Nutr       Date:  2009-03-18       Impact factor: 5.614

10.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.